Literature DB >> 31163102

Patient goals, motivations, and attitudes in a patient-driven variant reclassification study.

Ginger J Tsai1, Lauren Thomas Garrett1, Sukh Makhnoon2, Deborah J Bowen3, Wylie Burke3, Brian H Shirts1.   

Abstract

Family studies to reclassify clinically ascertained variants of uncertain significance (VUS) can impact risk assessment, medical management, and psychological outcomes for patients and their families. There are limited avenues for patients and their families to actively participate in VUS reclassification, and access to family studies at most commercial laboratories is restricted by multiple factors. To explore patient attitudes about participation in family studies for VUS reclassification, we conducted semistructured pre- and post-participation telephone interviews with 38 participants in a family-based VUS reclassification study that utilized a patient-driven approach for family ascertainment and recruitment. Participants had VUS from multigene panel testing performed at multiple clinical laboratories for cancer or other disease risk. Inductive thematic analysis of transcribed interviews highlighted four major themes: (a) Participants' study goals were driven by the desire to resolve uncertainty related to the VUS, (b) Participants had mixed reactions to the VUS reclassification outcomes of the study, (c) Personal, public, and familial knowledge increased through study participation and (d) Participants used study participation to actively cope with the uncertainty of a VUS. As personalized genomic medicine becomes more prevalent, clinicians, clinical laboratories, and researchers could consider creating more opportunities for active partnership with patients and families, who are motivated to contribute data to familial VUS studies.
© 2018 National Society of Genetic Counselors.

Entities:  

Keywords:  family studies; genetic research; health behavior; patient participation; patient-driven; qualitative research; thematic analysis; variant classification; variant of uncertain significance; variant reclassification

Mesh:

Year:  2018        PMID: 31163102     DOI: 10.1002/jgc4.1052

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  3 in total

1.  Exploring relatives' perceptions of participation, ethics, and communication in a patient-driven study for hereditary cancer variant reclassification.

Authors:  Ginger J Tsai; Annie T Chen; Lauren T Garrett; Wylie Burke; Deborah J Bowen; Brian H Shirts
Journal:  J Genet Couns       Date:  2020-01-09       Impact factor: 2.537

2.  What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?

Authors:  Deborah J Bowen; Sukh Makhnoon; Brian H Shirts; Stephanie M Fullerton; Eric Larson; James D Ralston; Kathleen Leppig; David R Crosslin; David Veenstra; Gail P Jarvik
Journal:  Patient Educ Couns       Date:  2021-01-07

3.  Patient perspectives on variant reclassification after cancer susceptibility testing.

Authors:  Colin M E Halverson; Laurie M Connors; Bronson C Wessinger; Ellen W Clayton; Georgia L Wiesner
Journal:  Mol Genet Genomic Med       Date:  2020-04-24       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.